Verona Pharma(VRNA) - 2024 Q4 - Annual Results

Financial Performance - The company anticipates net product sales of approximately $36 million for the fourth quarter ended December 31, 2024[6]. - As of December 31, 2024, Verona Pharma plc expects to report approximately $400 million in cash and cash equivalents[6]. Preliminary Results - These preliminary financial results are based on unaudited information and are subject to change[7]. - The independent registered public accounting firm has not conducted an audit or review of these preliminary estimates[7]. - The press release regarding these results was issued on January 7, 2025[9].